Press Releases
Calidi is at the forefront of the genetic medicine revolution in cancer and other indications
Read the Latest
Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform and Updates Anticipated Clinical Milestones
SAN DIEGO–(BUSINESS WIRE)–Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing…
Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Result
Announced first patient dosed by collaborator City of Hope in a Phase 1 clinical trial…
Calidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023)
Poster also details clinical readiness for CLDI-201 and plans to initiate Phase 1 study in…
Calidi Biotherapeutics Announces Key Leadership Promotions and New Board Appointment
Antonio F. Santidrian, PharmD, Ph.D., promoted to Chief Scientific Officer and Amish Patel, Ph.D., promoted…
Calidi Biotherapeutics Announces Appointment of Andrew Jackson as Chief Financial Officer
SAN DIEGO–(BUSINESS WIRE)– Calidi Biotherapeutics, Inc. (NYSEAM: CLDI) (or “Calidi”), a clinical-stage biotechnology company developing…
Calidi Biotherapeutics To Present New Preclinical Data Highlighting Cell-based Virotherapy (SuperNova) Platform Technology at SITC 2023
SAN DIEGO–(BUSINESS WIRE)– Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company…